The federal government has taken a major step toward reshaping U.S. cannabis policy, as the U.S. Department of Justice moves forward with a long-anticipated reclassification of marijuana. Acting Attorney General Todd Blanche announced that certain cannabis products will now be treated as less dangerous under federal law, marking the most significant shift since the Controlled Substances Act was enacted in 1970.
The decision follows a December executive order from Donald Trump directing officials to expedite the rescheduling process.
What Changed: Federal Cannabis Moves to Schedule III (For Some)
Under the new directive, cannabis products that are either approved by the FDA or produced by state-licensed medical marijuana operators are being immediately reclassified from Schedule I to Schedule III.
This change formally acknowledges cannabis as having accepted medical use in the United States – a monumental policy shift after more than five decades of being grouped alongside drugs like heroin and LSD.
According to Blanche, the move is designed to expand research opportunities and improve patient access to treatment.
A Phased Approach With Bigger Changes Ahead
The rescheduling process is not happening all at once. Instead, federal officials are rolling it out in phases:
- Immediate change: FDA-approved cannabis and state-licensed medical marijuana move to Schedule III.
- Next step: A new expedited administrative hearing begins June 29 to evaluate broader rescheduling.
- Timeline: The hearing is expected to conclude by mid-July, potentially paving the way for a final rule later this year.
This second phase could determine whether cannabis is fully rescheduled across all categories – not just medical.
What This Means for the Cannabis Industry
For medical cannabis operators, the change could bring meaningful financial relief and operational legitimacy. One of the biggest impacts involves Section 280E of the federal tax code, which has long prevented cannabis businesses from taking standard deductions.
With rescheduling:
- State-licensed medical operators may now qualify for federal tax deductions
- The federal government is encouraging retroactive tax relief, though it is not guaranteed
- Researchers gain expanded access to cannabis for scientific studies
Additionally, the new framework allows researchers to legally obtain cannabis from state-licensed businesses, removing a major barrier that has historically limited scientific progress.
What Hasn’t Changed
Despite the historic nature of the move, many core restrictions remain firmly in place:
- Cannabis is still federally illegal outside of the rescheduled categories
- Adult-use (recreational) cannabis is not included in the change
- Interstate commerce remains prohibited
- Banking access challenges persist
This creates a complicated legal landscape where medical and adult-use cannabis may be treated differently, even when involving the same products.
Regulatory Complexity and Industry Concerns
The partial rescheduling has already sparked confusion across the industry. Because Schedule III drugs are typically distributed through FDA-approved channels and DEA-registered pharmacies, questions remain about how state-licensed cannabis businesses will operate within – or alongside – this federal framework.
There are also logistical complexities tied to international treaty obligations, including a requirement that the federal government technically act as a purchaser in cannabis transactions before reselling products back to registered entities.
Industry leaders and legal experts say further clarification will be critical in the months ahead.
Legal Challenges Likely
Opposition groups have already indicated plans to challenge the rescheduling in court, setting the stage for potential delays or modifications to the policy.
At the same time, advocates and industry stakeholders view this moment as a major milestone in a decades-long effort to reform federal cannabis laws.
Bottom Line
The federal government’s decision to partially reschedule cannabis signals long-awaited recognition of its medical value and opens the door to research, tax relief, and regulatory evolution. However, with adult-use markets excluded and major legal questions unresolved, the path forward remains complex.
The next key moment will come this summer, when federal officials consider whether to extend these changes across the entire cannabis landscape.
Federal cannabis policy is shifting fast, and the gap between state operations and federal expectations is only getting more complex. With Schedule III changes now impacting medical operators (and broader reforms on the horizon), compliance is no longer optional – it’s a competitive advantage.
Is your business prepared for what’s next?
From navigating Section 280E tax changes to aligning with evolving federal registration requirements, the risks – and opportunities – are significant.
Partner with a cannabis compliance expert to:
- Identify gaps between your current operations and emerging federal standards
- Prepare for potential DEA and FDA oversight changes
- Optimize your tax strategy under new Schedule III rules
- Strengthen documentation, SOPs, and audit readiness
Don’t wait for enforcement to catch up… get ahead of it.
Contact us today to schedule a compliance audit and ensure your business is positioned to thrive in this new regulatory era.
